COMP <GO>
PHAT vs AQST // DIVIDEND YIELD & FCF PAYOUT SAFETY
Phathom Pharmaceuticals Inc. (NASDAQ) VS. Aquestive Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PHAT 4
— AQST 2
■ METRIC PARITY
LAST: $6.22 (-0.95%) • MKT CAP: $503.2M
dividend-safety
0.00%
LAST: $4.04 (-4.49%) • MKT CAP: $507.1M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PHAT VS. AQST)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PHAT | AQST | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.10% | 58.30% | +28.80 | PHAT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -10.45% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -0.10% | -60.00% | +59.90 | PHAT | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | -22.60% | +202.60 | PHAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | PHAT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.5 | 42.7 | -1.20 | AQST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $503.2M | $507.1M | -$3.9M | AQST | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PHAT REV | AQST REV | PHAT GROSS % | AQST GROSS % | PHAT FCF | AQST FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $175.1M | $44.5M | 87.1% | 58.3% | -$167.0M | -$53.0M |
| FY 2024 | $55.3M | $57.6M | 85.6% | 69.0% | -$266.9M | -$35.9M |
| FY 2023 | $682.0K | $50.6M | — | — | -$137.6M | -$6.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PHAT // BETA —
AQST // BETA —